Fluoroquinolones: Are They All the Same (Or Not) ?
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Role of Nanobiosensors in Therapeutic Drug Monitoring
Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2]. -
Activity of the Investigational Fluoroquinolone Finafloxacin and Seven Other PD Dr
Contact information: CORRESPONDING AUTHOR Activity of the Investigational Fluoroquinolone Finafloxacin and Seven Other PD Dr. Reiner Schaumann 49 th ICAAC Institute for Medical Microbiology and Epidemiology of Infectious Diseases San Francisco 2009 Antimicrobial Agents Against 83 Obligately Anaerobic Bacteria. University of Leipzig Liebigstr. 24 1 1 2 1 2 1 D-04103 Leipzig R. SCHAUMANN , G. H. GENZEL , W. STUBBINGS , C. S. STINGU , H. LABISCHINSKI , A. C. RODLOFF Germany E - 1973 Phone +49 341 97 15 200 1Inst. f. Med. Microbiology and Epidemiology of Infectious Diseases, Univ. of Leipzig, Leipzig, Germany; 2MerLion Pharmaceuticals GmbH, Berlin, Germany. Fax +49 341 97 15 209 E-Mail: [email protected] AbstractAbstract MethodsMethods ResultsResults andand DiscussionDiscussion Background: Finafloxacin (FIN) is a novel Bacterial Strains The Figures 2 and 3 show the scatter fluoroquinolone belonging to a 8-cyano subclass 83 obligately anaerobes including reference strains were taken from the histograms of MIC values obtained for FIN culture collection from the Institute for Medical Microbiology and and exhibits enhanced activity at slightly acidic and the seven other antimicrobial agents pH. FIN exhibited superior activity to comparator Epidemiology of Infectious Diseases, University of Leipzig, Germany. The fluoroquinolones in a wide range of rodent strains were collected from clinical specimens at the Institute and from against 83 obligately anaerobic bacteria infection models. With the present study the national and international studies and obtained in part from other included in this study. activity of FIN against 83 recently isolated strains laboratories. The following strains were used: Bacteroides fragils group of obligately anaerobic bacteria including (n=62): B. -
Download This PDF File
doi: http://dx.doi.org/10.5016/1806-8774.2009v11pT1 ARBS Annual Review of Biomedical Sciences Theme Topic on “Cell Receptors and Signaling” pdf freely available at http://arbs.biblioteca.unesp.br 2009;11:T1-T50 Story of Muscarinic Receptors, Alkaloids with Muscarinic Significance and of Muscarinic Functions and Behaviors Alexander G Karczmar* Research Service, Edward J. Hines VA Hospital and Department of Pharmacology, Loyola U. Medical Center, IL, USA Received: 23 October 2009; accepted 22 December 2009 Online on 21 February 2010 .Abstract Karczmar AG.. Story of Muscarinic Receptors, Alkaloids with Muscarinic Significance and of Muscarinic Functions and Behaviors. Annu Rev Biomed Sci 2009;11:T1-T50. This review of the studies of the muscarinic receptors, their synaptic activities and their functional and behavioral roles will begin with the history of the research of the autonomic and central nervous systems and their transmitters, the development of the notion of the receptor, and the tale of the significance of muscarine and other alkaloids as well as of organophosphorus (OP) anticholinesterases for these studies; we will then segue into the modern status of muscarinic receptors and of their functional and behavioral expression. © by São Paulo State University – ISSN 1806-8774 Keywords: muscarinic, cholinesterase, cholinergic, nicotinic, curare, atropine, behavior Table of Contents 1. Early Story of the Autonomic and Central Nervous System 2. The Early Story of Pharmacologically Active Alkaloids and of OP AntiChEs 3. From Gaskell’s and Langley’s Definition of Autonomic Nervous System to Loewi’s Demonstration of Peripheral Chemical, Cholinergic Transmission 4. Eccles’s Demonstration of Central Chemical, Cholinergic Transmission and Immediate Post-Ecclessian Studies of Central Nicotinic and Muscarinic Transmission 5. -
Paper I and II)
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1335 Constraints on up-regulation of drug efflux in the evolution of ciprofloxacin resistance LISA PRASKI ALZRIGAT ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6206 ISBN 978-91-554-9923-5 UPPSALA urn:nbn:se:uu:diva-320580 2017 Dissertation presented at Uppsala University to be publicly examined in B22, BMC, Husargatan 3, Uppsala, Friday, 9 June 2017 at 09:00 for the degree of Doctor of Philosophy (Faculty of Medicine). The examination will be conducted in English. Faculty examiner: Professor Fernando Baquero (Departamento de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain). Abstract Praski Alzrigat, L. 2017. Constraints on up-regulation of drug efflux in the evolution of ciprofloxacin resistance. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1335. 48 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-554-9923-5. The crucial role of antibiotics in modern medicine, in curing infections and enabling advanced medical procedures, is being threatened by the increasing frequency of resistant bacteria. Better understanding of the forces selecting resistance mutations could help develop strategies to optimize the use of antibiotics and slow the spread of resistance. Resistance to ciprofloxacin, a clinically important antibiotic, almost always involves target mutations in DNA gyrase and Topoisomerase IV. Because ciprofloxacin is a substrate of the AcrAB-TolC efflux pump, mutations causing pump up-regulation are also common. Studying the role of efflux pump-regulatory mutations in the development of ciprofloxacin resistance, we found a strong bias against gene-inactivating mutations in marR and acrR in clinical isolates. -
Liste Der Nobelpreisträger
Physiologie Wirtschafts- Jahr Physik Chemie oder Literatur Frieden wissenschaften Medizin Wilhelm Henry Dunant Jacobus H. Emil von Sully 1901 Conrad — van ’t Hoff Behring Prudhomme Röntgen Frédéric Passy Hendrik Antoon Theodor Élie Ducommun 1902 Emil Fischer Ronald Ross — Lorentz Mommsen Pieter Zeeman Albert Gobat Henri Becquerel Svante Niels Ryberg Bjørnstjerne 1903 William Randal Cremer — Pierre Curie Arrhenius Finsen Bjørnson Marie Curie Frédéric John William William Mistral 1904 Iwan Pawlow Institut de Droit international — Strutt Ramsay José Echegaray Adolf von Henryk 1905 Philipp Lenard Robert Koch Bertha von Suttner — Baeyer Sienkiewicz Camillo Golgi Joseph John Giosuè 1906 Henri Moissan Theodore Roosevelt — Thomson Santiago Carducci Ramón y Cajal Albert A. Alphonse Rudyard \Ernesto Teodoro Moneta 1907 Eduard Buchner — Michelson Laveran Kipling Louis Renault Ilja Gabriel Ernest Rudolf Klas Pontus Arnoldson 1908 Metschnikow — Lippmann Rutherford Eucken Paul Ehrlich Fredrik Bajer Theodor Auguste Beernaert Guglielmo Wilhelm Kocher Selma 1909 — Marconi Ostwald Ferdinand Lagerlöf Paul Henri d’Estournelles de Braun Constant Johannes Albrecht Ständiges Internationales 1910 Diderik van Otto Wallach Paul Heyse — Kossel Friedensbüro der Waals Allvar Maurice Tobias Asser 1911 Wilhelm Wien Marie Curie — Gullstrand Maeterlinck Alfred Fried Victor Grignard Gerhart 1912 Gustaf Dalén Alexis Carrel Elihu Root — Paul Sabatier Hauptmann Heike Charles Rabindranath 1913 Kamerlingh Alfred Werner Henri La Fontaine — Robert Richet Tagore Onnes Theodore -
Against Helicobacter Pylori in Vitro and in Vivo Merlion Pharmaceuticals Pte Ltd, Washington DC 2008 05-01 the Capricorn, 1 2 1 1 3 3 1 Science Park 2, A
Contact information: 48th ICAAC / 46th IDSA, WILL STUBBINGS Antimicrobial Activity of Finafloxacin (FIN) against Helicobacter pylori In Vitro and In Vivo MerLion Pharmaceuticals Pte Ltd, Washington DC 2008 05-01 The Capricorn, 1 2 1 1 3 3 1 Science Park 2, A. BUISSONNIÈRE , H-O. WERLING B. BERGEY , P. LEHOURS , W. STUBBINGS , H. LABISCHINSKI , F. MEGRAUD . Singapore 117528 F1-2038 Phone +65 6829 5600 1INSERM U853, Bordeaux, France, 2Bayer HealthCare AG, Elberfeld, Germany, 3MerLion Pharmaceuticals Pte Ltd, Singapore. [email protected] RevisedRevised abstractabstract MethodsMethods ResultsResults andand DiscussionDiscussion Introduction: FIN is a novel fluoroquinolone (FQ) belonging to a new 8- Minimum inhibitory concentration (MIC) determination Murine model of H. felis infection cyano subclass. FIN exhibits optimal efficacy at slightly acidic pH (5.0 - 6.0), Finafloxacin Levofloxacin Clearance % under which other FQs lose activity. FIN is intended for therapeutic use MICs were determined for FIN and LVX against H. pylori strains (n= 55) that were MIC MIC MIC MIC W 8801, X 7328, 17-8299, H. felis was passaged in mice to achieve a persistent infection that pH 50 90 50 90 X 2752, X 9181, Y 1304 against bacterial infections associated with an acidic environment such as H. obtained from patients gastroscoped in the Southwest of France. MICs were 100 [mg/L] [mg/L] [mg/L] [mg/L] 34-6601 exhibited a similar response to therapy as H. pylori in humans. Triple pylori eradication. The antibacterial activity of FIN, was determined against performed by agar dilution at 3 different pHs: 7.3, 6.3 and 5.3. An inoculum FIN FQ RES and susceptible strains at acidic pH, and against H. -
200 and 800 Mg) in Healthy Volunteers Receiving a Single Oral Dose
Pharmacology Chemotherapy 2011;57:97–107 Received: June 9, 2010 DOI: 10.1159/000321028 Accepted after revision: August 30, 2010 Published online: February 28, 2011 Urinary Pharmacokinetics and Bactericidal Activity of Finafloxacin (200 and 800 mg) in Healthy Volunteers Receiving a Single Oral Dose a b d Florian M.E. Wagenlehner Christine M. Wagenlehner Birgit Blenk d e e c Holger Blenk Sabine Schubert Axel Dalhoff Kurt G. Naber a Department of Urology, Pediatric Urology and Andrology, Justus Liebig University Giessen, and b c Department of Anesthesia, Evangelisches Krankenhaus, Giessen , Technical University of Munich, Straubing , d e Department of Microbiology, Nürnberg , and University Hospital Schleswig-Holstein, Campus Kiel, Kiel , Germany Key Words Introduction ؒ Finafloxacin ؒ Urine pharmacokinetics ؒ Pharmacodynamics Urinary bactericidal titers Urinary tract infection (UTI) is one of the most com- mon reasons for medical consultation. Uncomplicated UTI are predominantly caused by Escherichia coli, but Abstract also by Proteus mirabilis and occasionally Klebsiella spp., Background: Finafloxacin is a novel 8-cyano-fluoroquino- other Enterobacteriaceae and Staphylococcus saprophyti- lone under investigation for treatment of urinary tract infec- cus ( ! 5% each) [1–3] . Infections with P. mirabilis are sig- tion. Methods: Urinary concentrations and urinary bacteri- nificantly more common in patients over 50 years, where- cidal titers (UBT) of finafloxacin 200- and 800-mg single dos- as infections with S. saprophyticus are more common in es in 6 healthy volunteers were measured up to 48 h. UBT younger patients. Nosocomial UTI, almost always com- were determined for a reference strain and 9 selected clin- plicated, are caused by a wide range of pathogens, most ical uropathogens at the pH of native, acidified (pH 5.5) frequently E. -
Belgian Events - October 2013 Newsletter of the Embassy of Belgium in London Table of Contents Belgian Elections
Belgian Events - October 2013 Newsletter of the Embassy of Belgium in London Table of contents Belgian Elections Recent Highlights Interview with the Belgian Honorary Consul in Southampton Did you know? - Belgian awarded Nobel Prize for Physics - Belgium enjoys a very high reputation abroad - Belgian Food Industry launches website - Penguin to re-publish works by Georges Simenon - Belgian General popular on Wikipedia - Dr JP Vincent Fellow of Royal Society What's On? - Europalia.India - Chantal Akerman Retrospective - Belgian co-productions at London Film Festival - 'Hors les Murs' on DVD - Calendar of events Announcements - Embassy vacancy for a consular assistant - Dutch language classes for children Links to Representations, Clubs, Organisations Belgian Honorary Consulates ____________ ________________________________________________________________________ _______________ Belgian Elections (For our Belgian readers) The next federal elections in Belgium will most likely be held on 25 May 2014 in which case you can register to vote until 31 January 2014. Normally speaking, you will have received an election registration form by post a few weeks ago. On the form, you will need to fill in your election commune. Unlike for previous elections (2003, 2007 and 2010) you no longer have a choice in which commune you will cast your vote. This is now decided by law. You will also need to choose between one of five election options. In case you did not receive a form, please contact the Embassy as soon as possible: http://countries.diplomatie.belgium.be/en/united_kingdom/address_and_opening_times/ . Voting is compulsory for each Belgian national who is registered at the Embassy, is at least 18 years old at the time of the election and is not deprived of voting rights. -
Curt Von Euler 528
EDITORIAL ADVISORY COMMITTEE Albert J. Aguayo Bernice Grafstein Theodore Melnechuk Dale Purves Gordon M. Shepherd Larry W. Swanson (Chairperson) The History of Neuroscience in Autobiography VOLUME 1 Edited by Larry R. Squire SOCIETY FOR NEUROSCIENCE 1996 Washington, D.C. Society for Neuroscience 1121 14th Street, NW., Suite 1010 Washington, D.C. 20005 © 1996 by the Society for Neuroscience. All rights reserved. Printed in the United States of America. Library of Congress Catalog Card Number 96-70950 ISBN 0-916110-51-6 Contents Denise Albe-Fessard 2 Julius Axelrod 50 Peter O. Bishop 80 Theodore H. Bullock 110 Irving T. Diamond 158 Robert Galambos 178 Viktor Hamburger 222 Sir Alan L. Hodgkin 252 David H. Hubel 294 Herbert H. Jasper 318 Sir Bernard Katz 348 Seymour S. Kety 382 Benjamin Libet 414 Louis Sokoloff 454 James M. Sprague 498 Curt von Euler 528 John Z. Young 554 Curt von Euler BORN: Stockholm County, Sweden October 22, 1918 EDUCATION: Karolinska Institute, B.M., 1940 Karolinska Institute, M.D., 1945 Karolinska Institute, Ph.D., 1947 APPOINTMENTS: Karolinska Institute (1948) Professor Emeritus, Karolinska Institute (1985) HONORS AND AWARDS (SELECTED): Norwegian Academy of Sciences (foreign member) Curt von Euler conducted pioneering work on the central control of motor systems, brain mechanisms of thermoregulation, and on neural systems that control respiration. Curt von Euler Background ow did I come to devote my life to neurophysiology rather than to a clinical discipline? Why, in the first place, did I choose to study H medicine rather than another branch of biology or other subjects within the natural sciences? And what guided me to make the turns on the road and follow what appeared to be bypaths? There are no simple answers to such questions, but certainly a number of accidental circum- stances have intervened in important ways. -
The Grohe Method and Quinolone Antibiotics
The Grohe method and quinolone antibiotics Antibiotics are medicines that are used to treat bacterial for modern fluoroquinolones. The Grohe process and the infections. They contain active ingredients belonging to var- synthesis of ciprofloxacin sparked Bayer AG’s extensive ious substance classes, with modern fluoroquinolones one research on fluoroquinolones and the global competition of the most important and an indispensable part of both that produced additional potent antibiotics. human and veterinary medicine. It is largely thanks to Klaus Grohe – the “father of Bayer quinolones” – that this entirely In chemical terms, the antibiotics referred to for simplicity synthetic class of antibiotics now plays such a vital role for as quinolones are derived from 1,4-dihydro-4-oxo-3-quin- medical practitioners. From 1965 to 1997, Grohe worked oline carboxylic acid (1) substituted in position 1. as a chemist, carrying out basic research at Bayer AG’s Fluoroquinolones possess a fluorine atom in position 6. In main research laboratory (WHL) in Leverkusen. During this addition, ciprofloxacin (2) has a cyclopropyl group in posi- period, in 1975, he developed the Grohe process – a new tion 1 and also a piperazine group in position 7 (Figure A). multi-stage synthesis method for quinolones. It was this This substituent pattern plays a key role in its excellent achievement that first enabled him to synthesize active an- antibacterial efficacy. tibacterial substances such as ciprofloxacin – the prototype O 5 O 4 3 6 COOH F COOH 7 2 N N N 8 1 H N R (1) (2) Figure A: Basic structure of quinolone (1) (R = various substituents) and ciprofloxacin (2) Quinolones owe their antibacterial efficacy to their inhibition This unique mode of action also makes fluoroquinolones of essential bacterial enzymes – DNA gyrase (topoisomer- highly effective against a large number of pathogenic ase II) and topoisomerase IV. -
Nobel Peace Prize - True Or False?
Nobel Peace Prize - True or False? ___ 1 T he Nobel Peace Prize is ___ 7 The Nobel Peace Prize given every two years. ceremony is held each year in December. ___ 2 T he Nobel Peace Prize is n amed after a scientist. ___ 8 The Nobel Peace Prize winner is chosen by a ___ 3 A lfred Nobel was from c ommittee from Sweden. G ermany. ___ 9 T he prize can only be given ___ 4 N obel became very rich from t o one person each time. his invention – a new gasoline engine. ___ 10 T he Nobel Peace Prize consists of a medal, a ___ 5 There are six dierent Nobel diploma and some money. Prizes. ___ 6 The rst Peace Prize was awarded in 1946 . Nobel Peace Prize - True or False? ___F 1 T he Nobel Peace Prize is ___T 7 The Nobel Peace Prize given every two years. Every year ceremony is held each year in December. ___T 2 T he Nobel Peace Prize is n amed after a scientist. ___F 8 The Nobel Peace Prize winner is chosen by a Norway ___F 3 A lfred Nobel was from c ommittee from Sweden. G ermany. Sweden ___F 9 T he prize can only be given ___F 4 N obel became very rich from t o one person each time. Two or his invention – a new more gasoline engine. He got rich from ___T 10 T he Nobel Peace Prize dynamite T consists of a medal, a ___ 5 There are six dierent Nobel diploma and some money. -
List of Nobel Leaureates in Peace Year Laureates Country
List of Nobel Leaureates in Peace Year Laureates Country Rationale Henry Dunant Switzerland For his role in founding the International Committee of the Red Cross "For being one of the main founders of the Inter-Parliamentary Union and also the main organizer 1901 Frédéric Passy France of the first Universal Peace Congress" Élie Ducommun "For his role as the first honorary secretary of the International Peace Bureau" 1902 Charles Albert Gobat Switzerland "For his role as the first Secretary General of the Inter-Parliamentary Union" 1903 William Randal Cremer United Kingdom "For his role as the 'first father' of the Inter-Parliamentary Union" 1904 Institute of International Law Belgium "For its efforts as an unofficial body to formulate the general principles of the science of international law" 1905 Bertha von Suttner Austria-Hungary For writing Lay Down Your Arms and contributing to the creation of the Prize "For his successful mediation to end the Russo-Japanese war and for his interest in arbitration, 1906 Theodore Roosevelt United States having provided the Hague arbitration court with its very first case" Ernesto Teodoro Moneta Italy "For his work as a key leader of the Italian peace movement" 1907 Louis Renault France "For his work as a leading French international jurist and a member of the Permanent Court of Arbitration at The Hague" Klas Pontus Arnoldson Sweden "For his work as founder of the Swedish Peace and Arbitration League" "For being the foremost peace advocate in Scandinavia, combining work in the Inter-Parliamentary 1908